AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Iovance Biotherapeutics to Present at Wells Fargo Healthcare Conference and H.C. Wainwright Global Investment Conference
ByAinvest
Friday, Aug 29, 2025 8:34 am ET1min read
Iovance Biotherapeutics announced that senior leadership will present at the 2025 Wells Fargo Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference. The presentations will be webcast live and archived on the company's website. Iovance is focused on developing TIL therapies for cancer patients.
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company specializing in tumor infiltrating lymphocyte (TIL) therapies for cancer patients, has announced its participation in two upcoming investor conferences. The company will be presenting at the 2025 Wells Fargo Healthcare Conference on September 5, 2025, at 8:00 a.m. ET in Boston, MA, and the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 11:00 a.m. ET in New York, NY. Investors can access both live and archived webcasts of these presentations through the company's investor relations website [1].Iovance Biotherapeutics is focused on innovating, developing, and delivering novel polyclonal TIL therapies for patients with cancer. The company's Amtagvi® is the first FDA-approved T cell therapy for a solid tumor indication. Iovance is committed to continuous innovation in cell therapy, including gene-edited cell therapy, to extend and improve life for cancer patients [2].
The upcoming presentations will provide investors with an opportunity to gain insights into the company's progress in developing TIL therapies and its plans for future growth. Iovance's participation in these high-profile conferences underscores its commitment to transparency and engagement with the investment community.
References:
[1] https://www.stocktitan.net/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-v7ui9mtd90xw.html
[2] https://www.marketscreener.com/news/iovance-biotherapeutics-enters-amended-sale-agreement-with-jefferies-ce7c50dbdb8ff220
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet